Related Experiment Video
Updated: Feb 3, 2026

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells
1a Department of Laboratory Medicine , ShengJing Hospital of China Medical University , Shenyang , China.
Background:
Ixazomib (Ninlaro), a novel proteasome inhibitor, has been developed for the treatment of many cancers and has demonstrated anti-tumor efficacy against various malignancies. However, the mechanism of the anti-tumor effect of ixazomib in colorectal cancer (CRC) cells remains unclear.
Methods:
MTS and flow cytometry were performed to determine the effect of ixazomib on CRC cells. Western blotting and real-time RT-PCR were performed to detect ixazomib-induced DR5 upregulation. ChIP was performed to detect CHOP binding to DR5 promoter. Finally, xenograft experiments were carried out to measure the antitumor effect of ixazomib in vivo.
Results:
In this study, we revealed the mechanism by which ixazomib inhibits the growth of CRC cells. Our findings indicated that ixazomib treatment induces CHOP-dependent DR5 induction, irrespective of p53 status. Furthermore, DR5 is necessary for ixazomib-mediated apoptosis. Ixazomib also synergized with TRAIL to induce marked apoptosis via DR5 in CRC cells.
Conclusions:
Our findings further suggested that ixazomib sensitizes TRAIL/death receptor signaling pathway-targeted CRC and suggested that DR5 induction could be a valuable indicator of ixazomib sensitivity.
Insights
Ixazomib induces cancer cell death by upregulating DR5, a protein crucial for apoptosis. This proteasome inhibitor shows promise in colorectal cancer treatment, especially when combined with TRAIL therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Ixazomib is a proteasome inhibitor with demonstrated anti-tumor efficacy in various cancers.
- The precise mechanism of ixazomib's anti-tumor effects in colorectal cancer (CRC) cells is not fully understood.
Purpose of the Study:
- To elucidate the mechanism of ixazomib's anti-tumor activity in colorectal cancer cells.
- To investigate the role of DR5 and CHOP in ixazomib-induced apoptosis.
Main Methods:
- Cell viability assays (MTS) and flow cytometry were used to assess ixazomib's effects.
- Western blotting, RT-PCR, and ChIP assays were employed to analyze molecular changes.
- Xenograft experiments evaluated in vivo anti-tumor efficacy.
Main Results:
- Ixazomib treatment induced C/EBP homologous protein (CHOP)-dependent death receptor 5 (DR5) upregulation in CRC cells, independent of p53 status.
- DR5 expression was essential for ixazomib-induced apoptosis.
- Ixazomib synergized with TRAIL to enhance apoptosis through DR5.
Conclusions:
- Ixazomib inhibits CRC cell growth via CHOP-dependent DR5 induction and subsequent apoptosis.
- Ixazomib sensitizes colorectal cancer cells to TRAIL-mediated apoptosis.
- DR5 induction may serve as a predictive biomarker for ixazomib sensitivity.
More Related Videos
Related Concept Videos
Apoptosis
The Eukaryotic Promoter Region
The Eukaryotic Promoter Region
Frequency-dependent Selection
Contact-dependent Signaling
Gap Junctions
In animal cells, gap junctions are formed...
Induction
A...

